• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cardiovascular

R3 Vascular wins FDA IDE for drug-eluting scaffold

November 4, 2024 By Sean Whooley

R3 Vascular Logo

R3 Vascular announced today that the FDA granted investigational device exemption (IDE) to evaluate its Magnitude drug-eluting bioresorbable scaffold. Mountain View, California-based R3 Vascular designed Magnitude for treating below-the-knee (BTK) peripheral arterial disease (PAD). With the FDA granting IDE, it can now initiate the ELITE-BTK pivotal trial for the next-generation bioresorbable scaffold. R3 Vascular makes […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Stents, Vascular Tagged With: FDA, R3 Vascular

FDA approves IDE for Medtronic Prevail drug-coated balloon

October 23, 2024 By Sean Whooley

Medtronic logo updated

Medtronic (NYSE: MDT) announced today that it received FDA investigational device exemption (IDE) for its Prevail drug-coated balloon (DCB). The medtech giant can now begin a pivotal clinical trial for the coronary paclitaxel DCB for in-stent restenosis (ISR) and de novo small vessel disease. It plans to use data from its Prevail Global Clinical Program […]

Filed Under: Cardiovascular, Drug-Device Combinations, Food & Drug Administration (FDA), Regulatory/Compliance, Vascular Tagged With: FDA, Medtronic

CorFlow Therapeutics raises $48.5M for diagnostic, drug delivery platform

September 10, 2024 By Sean Whooley

CorFlow Logo (1)

CorFlow Therapeutics announced today that it raised €44 million ($48.5 million) to support its novel diagnostic and drug delivery platform. Broadview Ventures and Panakes Partners led the financing round. 415 Capital, Merieux Equity Partners, Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital also participated. […]

Filed Under: Business/Financial News, Cardiovascular, Clinical Trials, Diagnostics, Drug-Device Combinations, Funding Roundup, Implants Tagged With: CorFlow

Elutia announces first implant of drug-eluting bioenvelope for pacemakers and neurostimulators

September 6, 2024 By Sean Whooley

Elutia EluPro drug-eluting bioenvelope (1)

Elutia (Nasdaq:ELUT) announced the first-ever patient implant of its EluPro drug-eluting biologic envelope cleared by the FDA. Dr. John Catanzaro of the East Carolina University Health Medical Center in Greenville, North Carolina, performed the first procedure. Elutia says this marks the first implant of the world’s first antibiotic-eluting biologic envelope. Elutia designed EluPro to prevent […]

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Implants, Neurological Tagged With: Elutia

Reflow Medical enrolls first patient in coronary sirolimus-eluting retrievable scaffold system study

July 2, 2024 By Sean Whooley

Reflow Medical Logo

Reflow Medical announced that investigators enrolled the first patients in a trial of its Spur sirolimus-eluting retrievable scaffold system. DEEPER CORONARY evaluates the Spur Elute stent as a primary treatment for in-stent restenosis (ISR) of the coronary arteries. Spur Elute offers a treatment by transferring a proprietary drug formulation to the diseased lesion without leaving […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Implants, Stents, Vascular Tagged With: Reflow Medical

Cordis reports positive 2-year data for drug-eluting balloon

June 18, 2024 By Sean Whooley

Cordis Selution SLR drug-eluting balloon

Cordis today announced positive 24-month results from a study evaluating its Selution SLR drug-eluting balloon (DEB). Selution SLR offers endovascular therapy for de novo and non-stented restenotic lesions in the superficial femoral artery (SFA) and the popliteal artery (PA). Cordis acquired the DEB technology from MedAlliance for $1.135 billion last fall. The company presented data […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Vascular Tagged With: cordis

Elixir Medical wins FDA breakthrough nod for sirolimus-eluting bioadaptor system

June 18, 2024 By Sean Whooley

dynamx-elixir

Elixir Medical announced today that it received FDA breakthrough device designation for its DynamX bioadaptive implant. The breakthrough nod covers the improvement of coronary luminal diameter, restoration of hemodynamic modulation and reduction of plaque progression in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. It follows a March […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Elixir Medical Corporation

Surmodics to be acquired by private equity firm for $627M

May 29, 2024 By Sean Whooley

SurModics

Surmodics (Nasdaq:SRDX) announced today that it agreed to be acquired by GTCR, a private equity firm with healthcare interests. Eden Prairie, Minnesota-based Surmodics develops a range of technologies, including drug-coated balloons and thrombectomy systems. Its SurVeil DCB received a long-awaited FDA approval in June 2023. The company also reported successful early clinical use of its […]

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Mergers & Acquisitions, Vascular, Wall Street Beat Tagged With: Surmodics

Abbott wins FDA approval for dissolving drug-eluting scaffold

April 29, 2024 By Sean Whooley

Abbott Espirit BTK

Abbott [WtwhTicker symbol=”ABT”](NYSE: ABT)[/WtwhTicker] announced today that the FDA approved its Espirit everolimus-eluting resorbable scaffold system. The Espirit scaffold treats chronic limb-threatening ischemia (CLTI) below the knee (BTK). Abbott designed it to keep arteries open and deliver everolimus to support vessel healing prior to completely dissolving. According to a news release, no stents or drug-coated […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Stents, Vascular Tagged With: abbott, FDA

Concept Medical enrolls first patient in drug-coated balloon study

April 19, 2024 By Sean Whooley

Concept Medical

Concept Medical announced today that it commenced the FDA investigational device exemption (IDE) study of its MagicTouch system. MagicTouch, a sirolimus drug-coated balloon (DCB), treats in-stent restenosis (ISR) in coronary artery disease (CAD). Dr. Said Ashraf enrolled the first patient in the MAGICAL-ISR study at the AtlantiCare Institute in Atlantic City, New Jersey. The balloon […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Vascular Tagged With: conceptmedical

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 18
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS